Thiotepa-Based Stem Cell Transplant for Chronic Myelomonocytic Leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a chemotherapy regimen (thiotepa-containing preparation) combined with a stem cell transplant from a donor to treat chronic myelomonocytic leukemia (CMML), a rare blood cancer. The goal is to see if this approach helps patients with intermediate-to-high risk disease achieve remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed CMML diagnosis that is intermediate-2 or high-risk
- You are at least 18 years old
- You have a suitable stem cell donor (family member, matched unrelated donor, or partial match)
- Your heart, liver, kidneys, and lungs are functioning well enough for transplant
- You don't have active infections, HIV, hepatitis B or C, or recent stroke
- You're not pregnant, breastfeeding, or unwilling to commit to this treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new chemotherapy preparation (using thiotepa) before a stem cell transplant from a matched donor to treat blood cancers like leukemia and myelodysplastic syndrome. The goal is to improve survival while reducing severe side effects.
This Phase 1 trial tests a specific chemotherapy plan followed by a reduced-intensity donor stem cell transplant for people with relapsed or treatment-resistant acute myeloid leukemia (AML), certain myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). It may help by using donor stem cells to rebuild the bone marrow after intensive cancer treatment, in people who are not responding well to standard therapies.
This trial tests a modified conditioning regimen (a drug treatment given before a stem cell transplant) for people with chronic myeloid leukemia that has entered blast phase, an aggressive stage of the disease. The goal is to help prepare the body for a transplant and improve outcomes.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This trial tests a stem cell transplant (using donor cells) for people with a high-risk form of acute myeloid leukemia called CBF-AML. The goal is to see if this transplant can help patients who have a higher chance of the leukemia coming back.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
Hear when a new Chronic Myelomonocytic Leukemia (CMML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.